Sherbrooke Park Advisers LLC Sells 86,374 Shares of MiMedx Group, Inc. (NASDAQ:MDXG)

Sherbrooke Park Advisers LLC lowered its position in MiMedx Group, Inc. (NASDAQ:MDXG - Free Report) by 87.6% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 12,205 shares of the company's stock after selling 86,374 shares during the period. Sherbrooke Park Advisers LLC's holdings in MiMedx Group were worth $117,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of MDXG. JPMorgan Chase & Co. lifted its position in MiMedx Group by 265.4% during the third quarter. JPMorgan Chase & Co. now owns 297,367 shares of the company's stock valued at $1,757,000 after purchasing an additional 215,995 shares in the last quarter. Dimensional Fund Advisors LP lifted its position in MiMedx Group by 15.2% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,802,364 shares of the company's stock valued at $17,338,000 after purchasing an additional 238,075 shares in the last quarter. Raymond James Financial Inc. purchased a new position in MiMedx Group during the fourth quarter valued at $887,000. Tower Research Capital LLC TRC lifted its position in MiMedx Group by 77.4% during the fourth quarter. Tower Research Capital LLC TRC now owns 6,501 shares of the company's stock valued at $63,000 after purchasing an additional 2,837 shares in the last quarter. Finally, SG Americas Securities LLC lifted its position in shares of MiMedx Group by 79.9% in the fourth quarter. SG Americas Securities LLC now owns 83,385 shares of the company's stock valued at $802,000 after acquiring an additional 37,031 shares in the last quarter. Institutional investors own 79.15% of the company's stock.

MiMedx Group Price Performance

Shares of MiMedx Group stock traded up $0.18 during trading hours on Tuesday, hitting $6.81. The company's stock had a trading volume of 89,187 shares, compared to its average volume of 691,178. The business has a 50 day moving average price of $7.06 and a two-hundred day moving average price of $8.17. MiMedx Group, Inc. has a 12-month low of $5.47 and a 12-month high of $10.14. The company has a market cap of $1.01 billion, a PE ratio of 12.35 and a beta of 1.85. The company has a debt-to-equity ratio of 0.10, a quick ratio of 3.53 and a current ratio of 4.10.

MiMedx Group (NASDAQ:MDXG - Get Free Report) last issued its earnings results on Wednesday, April 30th. The company reported $0.06 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.06. MiMedx Group had a return on equity of 26.21% and a net margin of 23.86%. The firm had revenue of $88.21 million for the quarter, compared to analysts' expectations of $86.32 million. Analysts expect that MiMedx Group, Inc. will post 0.3 earnings per share for the current fiscal year.

Insider Transactions at MiMedx Group

In other news, CEO Joseph H. Capper bought 200,000 shares of MiMedx Group stock in a transaction dated Friday, May 2nd. The shares were purchased at an average cost of $6.34 per share, with a total value of $1,268,000.00. Following the completion of the acquisition, the chief executive officer now owns 529,530 shares of the company's stock, valued at $3,357,220.20. This trade represents a 60.69% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO William Frank Iv Hulse sold 81,446 shares of the business's stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $7.80, for a total value of $635,278.80. Following the sale, the chief accounting officer now directly owns 494,774 shares in the company, valued at $3,859,237.20. The trade was a 14.13% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 144,018 shares of company stock valued at $1,130,312. 1.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Wall Street Zen downgraded MiMedx Group from a "strong-buy" rating to a "buy" rating in a research report on Friday, May 9th. Cantor Fitzgerald restated an "overweight" rating and issued a $13.00 price objective on shares of MiMedx Group in a research report on Thursday, February 27th.

About MiMedx Group

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins.